303 related articles for article (PubMed ID: 26557822)
1. Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.
Schramm A; De Gregorio N; Widschwendter P; Fink V; Huober J
Breast Care (Basel); 2015 Jul; 10(3):173-8. PubMed ID: 26557822
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
3. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
Larionov AA
Front Oncol; 2018; 8():89. PubMed ID: 29670855
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review.
Sapna F; Athwal PSS; Kumar M; Randhawa S; Kahlon S
Cureus; 2020 Aug; 12(8):e9522. PubMed ID: 32905036
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
7. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
8. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
Mates M; Fletcher GG; Freedman OC; Eisen A; Gandhi S; Trudeau ME; Dent SF
Curr Oncol; 2015 Mar; 22(Suppl 1):S114-22. PubMed ID: 25848335
[TBL] [Abstract][Full Text] [Related]
9. Optimal treatment of early stage HER2-positive breast cancer.
Pernas S; Barroso-Sousa R; Tolaney SM
Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
[TBL] [Abstract][Full Text] [Related]
10. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.
Wilson FR; Coombes ME; Wylie Q; Yurchenko M; Brezden-Masley C; Hutton B; Skidmore B; Cameron C
Syst Rev; 2017 Oct; 6(1):196. PubMed ID: 29017563
[TBL] [Abstract][Full Text] [Related]
11. When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease.
Olson E; Mullins D
J Clin Trials; 2013 Mar; 3():1000129. PubMed ID: 24527366
[TBL] [Abstract][Full Text] [Related]
12. The expanding role of pertuzumab in the treatment of HER2-positive breast cancer.
Moya-Horno I; Cortés J
Breast Cancer (Dove Med Press); 2015; 7():125-32. PubMed ID: 26056489
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
14. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
15. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
16. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
